Evidence map›Paper›PMID 31333674›Full record

ArticleFrontiers in immunology2019

Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.

Eleni Maria Varypataki, Fabio Hasler, Ying Waeckerle-Men, Sarah Vogel-Kindgen, Anders Høgset, Thomas M Kündig, Bruno Gander, Cornelia Halin, Pål Johansen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Eleni Maria VarypatakiDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Fabio HaslerDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Ying Waeckerle-MenDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Sarah Vogel-KindgenInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Anders HøgsetPCI Biotech AS, Oslo, Norway.
Thomas M KündigDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
Bruno GanderInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Cornelia HalinInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Pål JohansenDepartment of Dermatology, University of Zurich, Zurich, Switzerland.
University of Zurich · CHETH Zurich · CHPCI Biotech (Norway) · NOUniversity Hospital of Zurich · CH

Funding

Swiss Cancer LeagueSwiss National Science Foundation
6 · The paper itself

Abstract

Cytotoxic T lymphocytes (CTLs) are key players in fighting cancer, and their induction is a major focus in the design of therapeutic vaccines. Yet, therapeutic vaccine efficacy is limited, in part due to the suboptimal vaccine processing by antigen-presenting cells (APCs). Such processing typically takes place via the MHC class II pathway for CD4 T-cell activation and MHC class I pathway for activation of CD8 CTLs. We show that a combination of skin photochemical treatment and immunization, so-called photochemical internalization (PCI) facilitated CTL activation due to the photochemical adjuvant effect induced by photosensitizer, oxygen, and light. Mice were immunized intradermally with antigen and photosensitizer, followed by controlled light exposure. PCI-treated mice showed strong activation of CD8 T cells, with improved IFN-γ production and cytotoxicity, as compared to mice immunized without parallel PCI treatment. Surprisingly, the CD8 T-cell effector functions were not impaired in MHC class II- or CD4 T-cell-deficient mice. Moreover, PCI-based vaccination caused tumor regression independent of MHC class II or CD4 T cells presence in melanoma bearing mice. Together, the data demonstrate that PCI can act as a powerful adjuvant in cancer vaccines, even in hosts with impaired T-helper functions.

Indexed as

AnimalsCancer VaccinesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorCytotoxicity, ImmunologicFemaleImmunizationInterferon-gammaLymphocyte ActivationMelanomaMiceMice, Inbred C57BLNeoplasmsPhotosensitivity DisordersPhotosensitizing AgentsCancer VaccinesInterferon-gammaPhotosensitizing Agentscancer immunotherapycytotoxic T cellsmelanomaphotochemical internalizationT-helper cellsvaccine

Identifiers

PMID31333674
PMCPMC6624637
OpenAlexW2951643480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.